Loading...
By Joe Elia
The FDA has ordered the personal genetics testing company 23andMe to suspend sales of its Saliva Collection Kit and Personal Genome Service because the company has not received the proper marketing clearance or approval.
The testing service assesses risks for BRCA-related cancer and warfarin sensitivity, among other things. Consumers order the $99 test directly from the company and may not be under a physician's care. "Serious concerns are raised if test results are not adequately understood by patients or if incorrect test results are reported," the FDA said in its warning letter.
A 23andMe spokesperson told the Associated Press: "Our relationship with the FDA is extremely important to us and we are committed to fully engaging with them to address their concerns."
Comment
LINK(S):
FDA warning letter (Free)
Associated Press story (Free)